Introduction
============

Patients with COPD experience exacerbations, some of which require hospitalization,[@b1-copd-11-1161] which accounts for a significant proportion of the £810--930 million economic cost annually[@b2-copd-11-1161] in the United Kingdom. Furthermore, exacerbations and admissions are associated with reduced physical functioning,[@b3-copd-11-1161],[@b4-copd-11-1161] which may contribute to the increased readmission risk.[@b5-copd-11-1161] The 28-day readmission rates arê33%,[@b2-copd-11-1161] and hospitals are penalized financially if patients get readmitted within 30 days of discharge.[@b6-copd-11-1161]

A patient survey[@b6-copd-11-1161] highlighted that individuals do not always feel able to cope at home postexacerbation. Additionally, patients report that they want more information and advice on practical coping issues,[@b6-copd-11-1161] highlighting the need for supportive interventions.

Pulmonary rehabilitation (PR) is one intervention that has increasingly been employed to address the reduced exercise capacity associated with exacerbations.[@b7-copd-11-1161],[@b8-copd-11-1161] PR consists of exercise and education to promote health-enhancing behaviors.[@b9-copd-11-1161] Rehabilitation offered early after hospital discharge can reduce readmission rates and improve exercise capacity,[@b7-copd-11-1161] but other studies have shown that it is difficult to recruit patients,[@b8-copd-11-1161] indicating that it may not be wholly acceptable during this period. Furthermore, no improvements in readmission rates or physical function were observed for an early intensive rehabilitation intervention over a longer, 12-month period,[@b10-copd-11-1161] highlighting the need for a different approach.

With finite health care resources, it is important to prevent unnecessary hospital admissions. Given the detrimental physical and emotional effects of hospitalization, it is important to devise an intervention to help reduce the associated impacts, while being safe and acceptable to patients.

Recent attention has been given to self-management interventions, from simple exacerbation management plans to comprehensive behavior-changing programs.[@b11-copd-11-1161] However, there have been concerns with these types of interventions, particularly after an acute exacerbation, as recent studies have observed increased mortality rates within the intervention arms.[@b10-copd-11-1161],[@b12-copd-11-1161] Although reasons for this have not been established, it has been postulated that patients may have misplaced confidence in their self-management skills.

A Self-management Program of Activity, Coping, and Education[@b13-copd-11-1161] for COPD (SPACE for COPD) improves clinical and health care utilization outcomes within a stable COPD population[@b14-copd-11-1161] but has not been investigated as a stand-alone intervention within an acute setting. SPACE for COPD is a brief intervention containing practical advice, a home-based exercise program, and an exacerbation action plan that aims to support patients to manage their day-to-day activities and promote health-enhancing behaviors.

Our hypothesis was that a structured self-management strategy (SPACE for COPD) employed upon hospital discharge would reduce readmissions for patients with COPD, compared to usual care. We also investigated the effect of SPACE for COPD on exercise tolerance, psychological impact, health-related quality of life, and disease knowledge.

Methods
=======

Design
------

A prospective, two-center, single-blinded randomized controlled trial was conducted during January 2013--September 2014. Participants provided written informed consent, and ethical approval was granted by National Research Ethics Service Committee West Midlands -- Solihull, reference 12/WM/0106, trial registration ISRCTN84599369.

Population
----------

Participants were recruited from University Hospitals Coventry and Warwickshire and University Hospitals of Leicester NHS Trusts. Participants were included if they had an established diagnosis of COPD and grade 2--5 dyspnea according to the Medical Research Council. Individuals were excluded if their reason for admission was not an acute exacerbation of COPD or if they were 1) unable to safely participate in unsupervised exercise (ie, due to psychiatric, locomotive, cardiac, or neurological impairments), 2) involved in other research, 3) unable to read English, 4) had previously received SPACE for COPD or completed PR within the previous 6 months, or 5) had four or more admissions in the previous 12 months.

Randomization
-------------

Participants were randomized to receive usual care or SPACE for COPD via a web-based, concealed allocation program ([www.sealedenvelope.com](http://www.sealedenvelope.com)) using simple random permuted block 1:1 randomization by VJ-W. Randomization was performed after the participants completed the baseline assessment, with treatment allocation prior to hospital discharge.

Usual care
----------

All participants received usual care during the study period. This consisted of a follow-up appointment with the community COPD team or telephone follow-up after an inpatient review by a respiratory nurse specialist and an outpatient consultant review. Due to waiting times, participants did not receive PR during the study period.

SPACE for COPD
--------------

SPACE for COPD has previously been described;[@b13-copd-11-1161] briefly, it comprises written educational information and a home-based exercise program (consisting of a daily walking-based aerobic program and thrice weekly resistance training using free weights of the upper and lower limbs). Participants were introduced to the manual and exercises by a trained physiotherapist (VJ-W) in a one-to-one session lasting 30--45 minutes, using motivational interviewing techniques to facilitate behavior change, goal setting, and problem solving. Participants were advised how to progress and that the manual could be valuable for the future to reinforce any life-long lifestyle changes. Participants received structured phone calls within 72 hours and at 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks from hospital discharge with the aim of reinforcing skills, helping identify and manage exacerbations, promoting an active lifestyle, and providing encouragement, while tailoring to patient needs. If participants get readmitted during the 3-month follow-up period, they continued the intervention as planned.

Outcome measures
----------------

The primary prespecified outcome measure was respiratory-related hospital readmission at 3 months. Secondary outcomes were the Chronic Respiratory Questionnaire -- self reported (CRQ-SR),[@b15-copd-11-1161] Hospital Anxiety and Depression Score,[@b16-copd-11-1161] Bristol COPD Knowledge Questionnaire,[@b17-copd-11-1161] Incremental Shuttle Walk Test (ISWT),[@b18-copd-11-1161] Endurance Shuttle Walking Test (ESWT),[@b19-copd-11-1161] Pulmonary Rehabilitation Adapted Index of Self-Efficacy,[@b20-copd-11-1161] and the "Ready for Home" survey.[@b6-copd-11-1161] All outcomes were measured at baseline (during admission but as close to discharge as possible) and 3 months after randomization, by a clinician blinded to treatment allocation. Mortality and readmission data were collected from hospital and primary care databases.

Sample size
-----------

Based on the primary outcome measure of readmission at 3 months, 36 participants were required in each arm to detect a fall in readmissions comparable to Seymour et al.[@b21-copd-11-1161] Calculations were based on 5% significance (alpha 0.05), 80% power, and two-tailed test using the SAS system.

Statistical analysis
--------------------

Data were tested for normality and appropriate parametric or nonparametric tests used. For binary variables (including primary outcome measure), Fisher's exact test was used to compare differences between the two groups. Odds ratios were calculated for 30-day readmissions. Independent *t*-tests or Kruskal--Wallis tests were used to compare between-group differences. Paired *t*-tests or Wilcoxon signed rank tests were used to compare within-group changes. Statistical significance was accepted if *P*\<0.05. Analysis was conducted on an intention-to-treat basis. Number (and percentages) of those achieving the known minimal clinically important differences of 0.5 for CRQ-SR,[@b22-copd-11-1161] −1.5 for Hospital Anxiety and Depression Score,[@b23-copd-11-1161] 47.5 m for ISWT,[@b24-copd-11-1161] and 186 seconds for ESWT[@b25-copd-11-1161] was calculated.

Protocol changes
----------------

Ethical approval was granted to reduce the time given to participants to consider study participation from 24 hours to whenever they felt they fully understood. This was to allow the inclusion of patients with a short hospital stay (ie, those with mild COPD exacerbations) or those discharged over a weekend.

Results
=======

The consort diagram ([Figure 1](#f1-copd-11-1161){ref-type="fig"}) describes the trial recruitment. Eighty-five patients consented, of whom 78 were randomized (39 to each arm) and included in the intention-to-treat analysis with 36 in usual care and 35 in SPACE for COPD available with follow-up data.

[Table 1](#t1-copd-11-1161){ref-type="table"} shows the baseline characteristics. No significant differences existed in baseline measures between groups (*P*\>0.05) or outcome measures between sites (*P*\>0.05). Twenty-two patients used home oxygen (ten used both long-term oxygen therapy and ambulatory, eight used solely long-term oxygen therapy, two ambulatory, and two palliative oxygen) at a mean (standard deviation) flow rate of 1.52 (0.57) L.

Primary outcome measure
-----------------------

Twenty-five patients (32.05%) were readmitted for respiratory reasons during the 3-month follow-up period: 13 receiving usual care and 12 receiving the intervention (33.33% vs 30.77%, *P*=0.808). [Figure 2](#f2-copd-11-1161){ref-type="fig"} shows the Kaplan--Meier curves.

Health care utilization
-----------------------

Readmission data were nonnormally distributed. Thirty-one patients (14 controls and 17 receiving the intervention, *P*=0.488) were readmitted for any reason during the 3-month period, with 44 admissions (21 in usual care and 23 in intervention, *P*=0.726). Respiratory reasons accounted for 79.55% of these readmissions (19 in usual care and 16 in SPACE for COPD, *P*=0.674).

[Table 2](#t2-copd-11-1161){ref-type="table"} shows the hospital length of stay for those who got readmitted. Median (interquartile range) days to first respiratory readmission was 14 (4--39) for usual care compared to 47 (4.5--55.5) for the intervention (*P*=0.341).

Ten usual care patients were readmitted within 30 days for respiratory reasons compared to five patients receiving the intervention (25.64% vs 12.82%, *P*=0.151), odds ratio (95% confidence interval) 0.426 (0.131--1.391), *P*\>0.05.

All participants were offered PR after the study period. Fourteen patients expressed an interest (seven in each group).

Mortality
---------

Within the 3-month study period, three usual care patients died (all due to respiratory reasons, median 65 days to death), whereas no patients receiving SPACE for COPD died, *P*=0.077. Data censored on September 30, 2014 (mean 339 days to censoring), revealed that seven usual care patients and three patients receiving SPACE for COPD had died, *P*=0.176.

Serious adverse events
----------------------

Only hospitalizations and mortality were reported as serious adverse events (SAEs). No other SAEs were found.

Exercise and questionnaire data
-------------------------------

ISWT and ESWT were nonnormally distributed. [Table 3](#t3-copd-11-1161){ref-type="table"} and [Figure 3](#f3-copd-11-1161){ref-type="fig"} show within- and between-group differences for quality of life, disease knowledge, exercise tolerance, and self-efficacy. Within-group changes (*P*\<0.05) were seen for both groups for all CRQ-SR domains except emotion for usual care (*P*=0.216). Between-group differences approached statistical significance for CRQ-dyspnea (*P*=0.062) and -emotion (*P*=0.077) domains, in favor of the intervention. Both groups significantly increased their exercise tolerance (*P*\<0.05). Disease-specific knowledge increased from baseline for those who received SPACE for COPD (*P*\<0.05) but not for usual care. [Table 4](#t4-copd-11-1161){ref-type="table"} shows that more patients who received the intervention achieved the minimal clinically important difference for CRQ-dyspnea (*P*=0.039).

At 3 months, [Table 5](#t5-copd-11-1161){ref-type="table"} shows how people felt upon their (initial) discharge from hospital from the Ready for Home survey. More patients following SPACE for COPD felt confident that medications could help and were reassured that good support was available at home compared to usual care (*P*\<0.05). [Table 6](#t6-copd-11-1161){ref-type="table"} shows that more patients in the SPACE for COPD arm felt that they were better able to arrange their life to cope with COPD, knew when to seek help about feeling unwell, and more often took their medications on time as prescribed, compared to usual care (all *P*\<0.05).

Discussion
==========

The supported self-management program, SPACE for COPD, delivered at the time of an acute exacerbation, did not reduce respiratory-related hospital readmissions at 3 months. However, benefits in quality of care and potential improvements in health-related quality of life, delaying time to first readmission, and reducing hospital length of stay were observed for those receiving the intervention. We did not find an increased mortality rate, and thus, SPACE for COPD appears a safe intervention in this population.

Within-group changes were observed for most outcomes for both groups. This gives further support that patients, after an acute exacerbation requiring hospitalization, experience a period of natural recovery.[@b10-copd-11-1161] There were encouraging trends for improved outcomes in those receiving SPACE for COPD compared to those receiving usual care, especially for CRQ-SR (with dyspnea and emotion scores improving by more than double for those receiving the intervention compared to usual care) and time to first readmission, although many did not reach statistical significance. This is likely due to the relatively small number of participants, so these secondary outcomes are likely to be underpowered.

Although not statistically significant, there were more admissions within the 30-day postdischarge period for respiratory reasons (attracting financial penalties of \~£2,000[@b26-copd-11-1161] each) in the group receiving usual care compared to the self-management group. Therefore, SPACE for COPD may be a feasible, brief intervention implementable immediately upon hospital discharge to help reduce this financial consequence and provide some benefits in quality of life and emotional support. Patients could then attend more intensive interventions when stable and natural recovery has plateaued, such as outpatient PR, which has established health and economic benefits.[@b27-copd-11-1161] However, we found that only 14 participants expressed an interest in attending PR. Furthermore, 164 patients declined to take part in this study. Reasons for this varied mainly from none being given to having done similar previous research or PR before, preferring to wait for PR, feeling "too old" or not well enough.

Previous studies[@b10-copd-11-1161],[@b12-copd-11-1161] have found an increased mortality rate in self-management interventions, which, although not fully understood, has caused safety concerns in delivering these types of interventions. We did not show an increased mortality rate (nor other SAEs) for those who received SPACE for COPD, compared to usual care; therefore, this particular intervention appears to be safe, at least in the short term. Previous authors[@b10-copd-11-1161] reasoned that their observed increased mortality rates could be due to either chance, failure to intervene or alterations in health behavior, which delay patients seeking medical advice. In our study, patients who received the self-management program reported that they better knew when to seek medical advice when feeling unwell, suggesting that they would not delay seeking advice. Furthermore, patients receiving SPACE for COPD also reported more often taking their medications on time as prescribed. These are positive behavior change perceptions; however, this did not translate into preventing readmissions.

Limitations to this study include recruitment constraints. Due to available resources, there was not complete coverage to recruit during peak admission periods on both sites. In addition, some inpatient stays were so brief that being able to perform all research procedures within a busy, acute clinical setting was difficult.

This study, along with others, has shown that it can be difficult to prevent hospital readmission in a sick population. To take on board all information during a relatively short introduction to our self-management program, while patients are unwell and may have impaired cognition,[@b28-copd-11-1161] may have contributed to the limited effectiveness of this intervention. Furthermore, all participants received specialist, usual care follow-up, and so their care could already be optimum. However, SPACE for COPD may help increase patient's self-management ability and confidence in the short term as displayed by the delay in time to readmission. It may be unreasonable to expect a reduction in readmission rates and arguably should not be seen as a negative outcome for the trial; it may be more realistic to anticipate a change in other aspects of successful disease management, for example, health-related quality of life. Analyses of qualitative interviews and health economic data may provide further insight into this and participants' compliance and adherence to the intervention.

Conclusion
==========

In conclusion, we found that SPACE for COPD, delivered upon hospital discharge and supported postdischarge, did not reduce readmission rate at 3 months compared to usual care alone. However, we did find that this supported self-management intervention provided some potential benefits in health-related quality of life and delaying time to first readmission, which appears safe, as additional mortality was not incurred, in contrast to findings from other recent studies.
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###### 

Baseline characteristics of the study population

  Characteristic                              Usual care      SPACE for COPD
  ------------------------------------------- --------------- ----------------
  Sex, male:female                            13:26           15:24
  Age, years                                  68.33 (7.73)    67.64 (8.54)
  FEV~1~, L                                   0.95 (0.36)     0.96 (0.45)
  FEV~1~, %                                   42.45 (11.73)   40.47 (15.71)
  FEV~1~/FVC ratio, %                         42.77 (10.54)   47.09 (13.95)
  Body mass index                             23.75 (5.61)    25.49 (5.97)
  Smoking status (n)                                          
   Current:Ex:Never                           18:21:0         14:24:1
  Smoking pack years                          48.33 (29.02)   52.39 (34.32)
  Disease duration, years                     6.90 (5.99)     7.89 (7.43)
  Marital status (n)                                          
   Married:partner:divorced: widowed:single   12:2:11:12:2    18:4:8:7:2
  Lives (n)                                                   
   Alone:with partner:with family             19:12:8         14:17:8
  GOLD stage (n)                                              
   I:II:III:IV                                0:10:12:12      0:10:16:11
  Medical Research Council dyspnea grade      4 (3--5)        4 (3--5)
   2:3:4:5 (n)                                6:5:13:15       4:7:12:16
  Exercise history (n)                                        
   Current:previous:never                     6:22:11         6:20:13

**Note:** Values are mean (SD) or median (interquartile range).

**Abbreviations:** SD, standard deviation; SPACE, Self-management Program of Activity, Coping, and Education; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for chronic Obstructive Lung Disease.

###### 

Hospital length of stay (for readmission)

                       Usual care         SPACE for COPD     Between-group difference
  -------------------- ------------------ ------------------ --------------------------
  Intention-to-treat                                         
   All-cause           16.5 (3.8--39.8)   9.0 (1.0--30.0)    *P*=0.218
   Respiratory         15.0 (3.5--32.0)   12.0 (9.0--33.8)   *P*=0.341
   Nonrespiratory      27.0 (7.5--33.8)   1.0 (1.0--3.0)     *P*=0.067
  Per protocol                                               
   All-cause           13.0 (3.3--25.5)   9.0 (1.0--27.8)    *P*=0.381
   Respiratory         11.0 (3.0--21.0)   11.0 (8.8--37.5)   *P*=0.597
   Nonrespiratory      27.0 (7.5--33.8)   1.0 (0.8--2.0)     *P*=0.044

**Note:** Values are median (interquartile range) days.

**Abbreviation:** SPACE, Self-management Program of Activity, Coping, and Education.

###### 

Baseline and change in secondary outcome measures at 3 months

                    Usual care        SPACE for COPD                                                    Between-group difference                                                                            
  ----------------- ----------------- ----------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------ -----------
  CRQ-dyspnea       2.22 (0.95)       0.45 (1.17)[\*](#tfn5-copd-11-1161){ref-type="table-fn"}          2.36 (0.99)                1.05 (1.26)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}               *P*=0.062
  CRQ-fatigue       2.40 (0.97)       0.62 (1.21)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}        2.23 (1.08)                0.99 (1.22)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}               *P*=0.245
  CRQ-emotion       3.41 (1.29)       0.37 (1.60)                                                       3.12 (0.99)                1.09 (1.51)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}               *P*=0.077
  CRQ-mastery       3.24 (1.36)       0.89 (1.51)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}        2.81 (1.11)                1.41 (1.48)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}               *P*=0.181
  ISWT (m)          60 (10--167.50)   30 (0--95)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}         60 (30--150)               45 (0--70)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}                *P*=0.769
  ESWT (seconds)    50 (0--171)       155 (21--618.50)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}   110 (8--196.50)            178.5 (−3.75 to 443.50)[\*\*](#tfn6-copd-11-1161){ref-type="table-fn"}   *P*=0.951
  HADS-anxiety      7.79 (3.84)       0.28 (3.48)                                                       9.62 (4.33)                −0.27 (3.45)                                                             *P*=0.563
  HADS-depression   7.18 (3.18)       0.76 (4.30)                                                       6.97 (4.18)                0.54 (3.29)                                                              *P*=0.833
  PRAISE            39.08 (9.40)      2.34 (8.73)                                                       40.15 (7.73)               0.54 (9.48)                                                              *P*=0.465
  BCKQ              31.71 (9.21)      2.10 (7.19)                                                       33.90 (8.38)               3.92 (7.14)[\*](#tfn5-copd-11-1161){ref-type="table-fn"}                 *P*=0.364

**Notes:** Mean (SD) or median (IQR) are reported as appropriate.

*P*\<0.05 within-group difference,

*P*\<0.01 within-group difference.

**Abbreviations:** SD, standard deviation; IQR, interquartile range; SPACE, Self-management Program of Activity, Coping, and Education; CRQ, Chronic Respiratory Questionnaire; ISWT, Incremental Shuttle Walk Test; ESWT, Endurance Shuttle Walk Test; HADS, Hospital Anxiety and Depression Scale; PRAISE, Pulmonary Rehabilitation Adapted Index of Self-Efficacy; BCKQ, Bristol COPD Knowledge Questionnaire.

###### 

Number (%) of participants who achieved the MCID

                    Usual care    SPACE for COPD   Between-group difference
  ----------------- ------------- ---------------- --------------------------------------------------------
  CRQ-dyspnea       11 (36.67%)   19 (63.33%)      *P*=0.039[\*](#tfn8-copd-11-1161){ref-type="table-fn"}
  CRQ-fatigue       17 (56.67%)   23 (76.67%)      *P*=0.104
  CRQ-emotion       17 (56.67%)   19 (63.33%)      *P*=0.605
  CRQ-mastery       22 (73.33%)   22 (73.33%)      *P*=1.000
  ISWT              9 (42.86%)    11 (50%)         *P*=0.648
  ESWT              8 (47.06%)    10 (50%)         *P*=0.863
  HADS-anxiety      5 (17.24%)    9 (34.62%)       *P*=0.151
  HADS-depression   10 (34.48%)   8 (30.77%)       *P*=0.775

**Note:**

*P*\<0.05.

**Abbreviations:** MCID, minimal clinically important difference; CRQ, Chronic Respiratory Questionnaire; ISWT, Incremental Shuttle Walk Test; ESWT, Endurance Shuttle Walk Test; HADS, Hospital Anxiety and Depression Scale; SPACE, Self management Programme of Activity Coping and Education.

###### 

How people feel upon discharge from hospital following treatment for their COPD (% per group)

                                                       Very   Fairly   Neither yes or no   Not really   Not at all   Don't know   Between-group differences                         
  ---------------------------------------------------- ------ -------- ------------------- ------------ ------------ ------------ --------------------------- ---- ---- --- --- --- ---------------------------------------------------------
  Ready (well enough) to leave hospital                39     43       39                  33           7            0            11                          20   4    0   0   3   *P*=0.976
  Reassured about being able to cope at home           36     53       29                  23           7            7            21                          13   4    3   0   0   *P*=0.230
  Informed about your COPD and reasons for admission   29     47       21                  27           11           0            18                          13   7    3   7   3   *P*=0.086
  Confident about how/when to take medications         68     70       18                  20           4            0            11                          3    0    0   0   0   *P*=0.444
  Confident that COPD medications could help           46     67       36                  30           4            3            14                          0    0    0   0   0   *P*=0.049[\*](#tfn11-copd-11-1161){ref-type="table-fn"}
  Reassured that good support was available at home    46     67       18                  23           14           3            7                           0    7    3   7   0   *P*=0.022[\*](#tfn11-copd-11-1161){ref-type="table-fn"}
  Positive about the future                            18     27       29                  43           18           10           17                          10   10   0   0   0   *P*=0.156

**Notes:** Not all participants completed each question; therefore, not all scores total 100%.

*P*\<0.05.

**Abbreviations:** UC, usual care; SM, self-management (Self management Programme of Activity, Coping and Education (SPACE)).

###### 

Effect of (baseline) hospitalization on how people felt they changed and consequently managed their COPD (%)

                                                        Increased/better/more often   No change   Reduced/worsened/less often   Between-group difference             
  ----------------------------------------------------- ----------------------------- ----------- ----------------------------- -------------------------- ---- ---- ---------------------------------------------------------
  Your level of exercise and general activities         14                            37          57                            43                         29   20   *P*=0.097
  Your ability to arrange your life to cope with COPD   11                            50          79                            40                         11   10   *P*=0.012[\*](#tfn14-copd-11-1161){ref-type="table-fn"}
  Taking your medications on time as prescribed         17                            57          71                            43                         4    0    *P*=0.017[\*](#tfn14-copd-11-1161){ref-type="table-fn"}
  Knowing when to seek help about feeling unwell        43                            73          57                            23                         0    3    *P*=0.038[\*](#tfn14-copd-11-1161){ref-type="table-fn"}
  Your efforts to give up/avoid smoking                 36                            40          46                            37                         7    3    *P*=0.438
  Your participation in discussion forums/groups        0                             13          75                            67                         7    7    *P*=0.161
  The use of available community support services       4                             30          82                            60                         11   3    *P*=0.058

**Notes:** Not all participants completed each question; therefore, not all scores total 100%.

*P*\<0.05.

**Abbreviations:** UC, usual care; SPACE, Self-management Program of Activity, Coping, and Education.
